Cost effectiveness of immune checkpoint inhibitors in NSCLC according to PD-L1 expression.

被引：3
|
作者：
Aguiar, Pedro Nazareth
Tadokoro, Hakaru
Barreto, Carmelia Maria Noia
Santoro, Ilka Lopes
De Mello, Ramon Andrade
Babiker, Hani M.
Avancha, Kiran
Lopes, Gilberto
机构：
[1] Univ Fed Sao Paulo, Sao Paulo, Brazil
[2] Univ Algarve, Dept Biomed Sci & Med, Faro Med Oncol & Res Ctr, Faro, Portugal
[3] HonorHlth Res Inst, Virginia G Piper Canc Ctr Clin Trials, Scottsdale, AZ USA
[4] HonorHlth Res Inst, Scottsdale, AZ USA
[5] Inst Canc Estado Sao Paulo, Clin Oncol, Sao Paulo, Brazil
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.9033
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9033
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Cost-effectiveness of immune checkpoint inhibitors in NSCLC according to PD-L1 expression
    Aguiar, Pedro, Jr.
    Perry, Luke A.
    Lopes, Gilberto L., Jr.
    LUNG CANCER MANAGEMENT, 2016, 5 (03) : 119 - 122
  • [2] Cost effectiveness and estimate of economical impact of immune checkpoint inhibitors for NSCLC relative to PD-L1 expression
    Aguiar Junior, P. N.
    De Mello, R.
    Tadokoro, H.
    Babiker, H. M.
    Lopes, G., Jr.
    ANNALS OF ONCOLOGY, 2016, 27
  • [3] Efficacy of PD-1/PD-L1 Immune Checkpoint Inhibitors for Advanced NSCLC According to PD-L1 Expression: A Meta-Analysis
    Ma, K.
    Guo, Y.
    Wang, Y.
    Wang, X.
    Xu, Y.
    Sun, C.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S584 - S584
  • [4] Response to 'The effect of PD-L1 testing on the cost-effectiveness of immune checkpoint inhibitors'
    Ogale, S.
    ANNALS OF ONCOLOGY, 2018, 29 (10) : 2140 - 2140
  • [5] Estimate of Economic Impact of Immune Checkpoint Inhibitors for NSCLC Relative to PD-L1 Expression in the US
    Aguiar, Pedro, Jr.
    De Mello, Ramon
    Tadokoro, Hakaru
    Babiker, Hani
    Gutierres, Barbara
    Lopes, Gilberto
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S308 - S308
  • [6] Cost Effectiveness of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer Relative to PD-L1 Expression
    Aguiar, Pedro, Jr.
    De Mello, Ramon
    Tadokoro, Hakaru
    Santoro, Ilka
    Babiker, Hani
    Avancha, Kiran
    Gutierres, Barbara
    Barreto, Carmelia
    Lopes, Gilberto
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (10) : S169 - S170
  • [7] Co-expression patterns of immune checkpoint molecules in relation to PD-L1 expression.
    Pal, Sumanta K.
    Vanderwalde, Ari M.
    Szeto, Christopher
    Benz, Stephen Charles
    Sanborn, John Zachary
    Vaske, Charles Joseph
    Reddy, Sandeep K.
    Hamid, Omid
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [8] Immune checkpoint inhibitors' (ICI) efficacy according to PD-L1 expression for advanced or metastatic NSCLC: Systematic review and meta-analysis.
    Maciel, Glauber
    Carlos, Paula
    Murad Junior, Munir
    Araujo, Vania Eloisa
    Guerra, Augusto
    Acurcio, Francisco Assis
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [9] The effect of PD-L1 testing on the cost-effectiveness and economic impact of immune checkpoint inhibitors for the second-line treatment of NSCLC
    Aguiar, P. N., Jr.
    Perry, L. A.
    Penny-Dimri, J.
    Babiker, H.
    Tadokoro, H.
    de Mello, R. A.
    Lopes, G. L., Jr.
    ANNALS OF ONCOLOGY, 2017, 28 (09) : 2256 - 2263
  • [10] Efficacy of Immune-Checkpoint Inhibitors and EGFR-TKIs in NSCLC Patients with High PD-L1 Expression
    Masuda, K.
    Horinouchi, H.
    Tanaka, M.
    Higashiyama, R.
    Shinno, Y.
    Sato, J.
    Yoshida, T.
    Matsumoto, Y.
    Goto, Y.
    Kanda, S.
    Yamamoto, N.
    Ohe, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S292 - S293
12345